The primary goal of the Mass Spectrometry Resource (MSR) is to provide comprehensive mass spectral and, in the near future, biophysical analyses to investigate within the YCC. The instrumentation required to meet this goal is invariably expensive and requires considerable expertise to operate and to properly interpret the resulting data. The Resource is equipped with a VG-ZAB-SE high resolution, high mass range mass spectrometer equipped with EI and FAB (35 kV Cesium ion) ion sources. The instrument is used to provide low and high resolution mass spectral analyses. The Resource has a Micro-mass Quattro model triple quadrupole instrument equipped with an electrospray ion source manufactured by Analytica, Inc(Branford, CT). This ion source also contains a nanoflow probe. Samples can be introduced by either direct infusion or by HPLC. The Resource is also affiliated with the W.M. Keck Biotechnology Resource in which are housed a Finnegan LCQ and a Micro-mass TofSpec MALDI mass spectrometers ensuring that a wide variety of mass spectral instrumentation can be applied to any sample. The Resource welcomes inquires on the applicability of mass spectrometry to a particular bioanalytical problem. The operation of the MSR is supported by users fees, the Cancer Center Support Grant and the YCC. Questions can be addressed to Walter McMurray at 203-785-6169 or by e-mail at walter.mcmurray@yale.edu.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-25
Application #
6203016
Study Section
Project Start
1999-08-12
Project End
2000-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270

Showing the most recent 10 out of 675 publications